ClinicalTrials.gg
CompletedNCT01853254Updated Sep 4, 2013Results posted

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

A Phase 3 interventional study of Peginterferon alfa-2a and Ribavirin in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 67 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-04.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
272
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
23rd of 83
272 · median 129
Started
2003
with 11 others
Phase 3
19 of 83
none open now
Registered
74th of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 23rd largest by enrollment, is one of 12 that started in 2003, is one of 19 in phase 3, and was the 74th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This open-label, non-randomized, single arm study will provide treatment or re-treatment with Pegasys (peginterferon alfa-2a) as monotherapy or in combination with Copegus (ribavirin) to patients with chronic hepatitis C infection. Patients who have received prior Pegasys monotherapy or combination therapy or who were considered eligible for treatment with Pegasys in previous donor protocols will be eligible to participate in this study. Treatment will be on investigator's decision according to the approved label for up to 48 weeks, with a 24-week safety follow-up.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, ≥ 18 years of age.
  • Chronic .
  • Compensated liver disease ( Class A).
  • Previous participation in a donor protocol in which treatment or re-treatment with Pegasys alone or in combination with Copegus was recommended or deemed appropriate after study completion.
  • Have completed safety and efficacy assessments as defined in the donor protocol without violation or any major deviation.
  • Have not received any other anti-hepatitis C virus treatment after the completion of the donor protocol.
  • For females of , a negative pregnancy test within 24 hours prior to first dose of study drug.
  • Fertile patients (male and female) must use 2 reliable forms of (combined) for the duration of the study (treatment and follow-up) in accordance with the locally approved label for Copegus.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Male partners of women who are pregnant.
  • Patients with hemoglobinopathies.
  • Hepatic decompensation ( Class B or C) before or during treatment.
  • Non-responder patients (defined as patients previously treated with Pegasys and Copegus combination therapy at standard doses for at least 12 weeks who did not achieve at least a 2-log drop from their baseline viral load).
  • Liver disease other than chronic , including hepatic carcinoma.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
272 participants (actual)

Study arms

  • Experimental
    Peginterferon alfa-2a monotherapy or combined with ribavirin

    The treating investigator decided the most appropriate treatment. It was recommended that participants receive combination therapy.

    Drug: Peginterferon alfa-2a · Drug: Ribavirin

Interventions

  • Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.

    Also known as: Pegasys

  • For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing \< 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.

    Also known as: Copegus

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least 1 Adverse Event

    Time frame: From Baseline to the end of the study (up to 72 weeks)

07

Results

Posted Sep 4, 2013

Participant flow

Participant flow — Overall Study
MilestonePeginterferon Alfa-2a Monotherapy or Combined With Ribavirin
Started272
Completed168
Not completed104
Withdrew: Abnormal laboratory test1
Withdrew: Adverse event/intercurrent illness3
Withdrew: Death1
Withdrew: Failure to return43
Withdrew: Insufficient therapeutic response22
Withdrew: Refusal of treatment1
Withdrew: Other protocol violation1
Withdrew: Withdrawal of consent16
Withdrew: Administrative/other16

Outcome measures

PrimaryPercentage of Participants With at Least 1 Adverse Event
Time frame:
From Baseline to the end of the study (up to 72 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With at Least 1 Adverse Event
Percentage of participantsPeginterferon Alfa-2a Monotherapy or Combined With Ribavirin
Percentage of Participants With at Least 1 Adverse Event38.2

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin—17/272 (6.3%)39/272 (14.3%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventPeginterferon Alfa-2a Monotherapy or Combined With Ribavirin
AnemiaBlood and lymphatic system disorders2/272
Angina pectorisCardiac disorders1/272
PalpitationsCardiac disorders1/272
Amaurosis fugaxEye disorders1/272
CholecystitisHepatobiliary disorders1/272
CholelithiasisHepatobiliary disorders1/272
CellulitisInfections and infestations1/272
Cryptosporidiosis infectionInfections and infestations1/272
GastroenteritisInfections and infestations1/272
ContusionInjury, poisoning and procedural complications1/272
Most frequent other events
Most frequent other events
EventPeginterferon Alfa-2a Monotherapy or Combined With Ribavirin
NeutropeniaBlood and lymphatic system disorders22/272
AnaemiaBlood and lymphatic system disorders21/272

Baseline characteristics

Age Continuous
Age Continuous(years)Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin
Mean48.3 ± 9.50
Sex: Female, Male
Sex: Female, Male(Participants)Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin
Female90
Male182
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin
Black24
Caucasian189
Oriental6
Other53
Height
Height(Centimeters (cm))Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin
Mean172.4 ± 10.22
Weight
Weight(Kilograms (kg))Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin
Mean85.72 ± 19.803
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Peginterferon Alfa-2a Monotherapy or Combined With Ribavirin
Mean28.8 ± 5.89
08

Study locations

67 sites
  • Birmingham, Alabama 35295-0005, United States
  • La Jolla, California 92037-1030, United States
  • Long Beach, California 90822, United States
  • San Diego, California 92123, United States
  • San Diego, California 92154, United States
  • San Francisco, California 94115, United States
  • Aurora, Colorado 80045, United States
  • Gainesville, Florida 32610-0214, United States
  • Gainesville, Florida 32610, United States
  • Jacksonville, Florida 32209, United States
  • Miami, Florida 33136-1051, United States
  • Orlando, Florida 32803, United States
  • Orlando, Florida 32809, United States
  • Sarasota, Florida 34243, United States
  • Wellington, Florida 33414, United States
  • Atlanta, Georgia 30308, United States
  • Atlanta, Georgia 30309, United States
  • Marietta, Georgia 30060, United States
  • Honolulu, Hawaii 96817, United States
  • Boise, Idaho 83702, United States
  • Indianapolis, Indiana 46202, United States
  • Iowa City, Iowa 52242, United States
  • Kansas City, Kansas 66160, United States
  • Baltimore, Maryland 21205, United States
  • Framingham, Massachusetts 01702, United States
  • Worcester, Massachusetts 01655, United States
  • Plymouth, Minnesota 55446, United States
  • Newark, New Jersey 07102, United States
  • Vineland, New Jersey 08360, United States
  • Binghamton, New York 13903, United States
  • Manhasset, New York 11030, United States
  • New York, New York 10016, United States
  • New York, New York 10021, United States
  • Poughkeepsie, New York 12601, United States
  • Durham, North Carolina 27710, United States
  • Statesville, North Carolina 28677, United States
  • Cleveland, Ohio 44106, United States
  • Portland, Oregon 97201, United States
  • Lancaster, Pennsylvania 17604-3200, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Providence, Rhode Island 02905, United States
  • Germantown, Tennessee 38138, United States
  • Dallas, Texas 75203, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78215, United States
  • Charlottesville, Virginia 22906-0013, United States
  • Bellevue, Washington 98004, United States
  • Seattle, Washington 98133, United States
  • Tacoma, Washington 98403, United States
  • Adelaide, 5000, Australia
  • Herston, 4006, Australia
  • Ribeirao Preto, 14049-900, Brazil
  • Salvador, 40150-130, Brazil
  • Sao Paulo, 01246-000, Brazil
  • Sao Paulo, 1323020, Brazil
  • Vandoeuvre-les-nancy, 54511, France
  • Thessaloniki, 56429, Greece
  • Bergamo, 24128, Italy
  • Napoli, 80131, Italy
  • Warszawa, 01-201, Poland
  • Ponce, 00716, Puerto Rico
  • San Juan, 00921-3200, Puerto Rico
  • San Juan, 00936-5067, Puerto Rico
  • Santurce, 00909, Puerto Rico
  • Barcelona, 08803, Spain
  • Taoyuan, 333, Taiwan
  • Plymouth, PL6 8DH, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2013, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2013
First posted
May 14, 2013
Start
Sep 2003
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results first posted
Sep 4, 2013
Last update
Sep 4, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01853254
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
May 14, 2013
Start date
Sep 2003
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Sep 4, 2013
Last update
Sep 4, 2013

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2a · Ribavirin

Start the discussion